Eric P. Milledge, PhD, Chairman, is a retired company group chairman of Johnson & Johnson. He was responsible for LifeScan, Inc., and was also a member of the Medical Devices & Diagnostics Group Operating Committee. He previously held positions of Company Group Chairman of Johnson & Johnson Health Care Systems, Inc., President of Ortho-McNeil, and President of Ortho Pharmaceutical Corporation.
Reinhard J. Ambros, PhD, is Executive Director of Novartis Venture Fund. Previously, he worked with Novartis Corporate Finance where he held the position of Head of Group Strategic Planning for several years. He was responsible for post merger integrations at Novartis Corporate M & A and was global head BD & L cardiovascular and metabolic diseases at Novartis Pharma. Earlier in his career he had global leadership positions for key drug development projects at Novartis and Roche.
Jacques R. Essinger, PhD, is the CEO of Symetis. He started his career as R&D director of a US based CT scan image processing company, followed by co-founding and CEO of an orthopedics company in CH, general manager position of a US based surgical tool company, and then becoming CEO of CH based IsoTis Ortho Biologics, which he led from 1997 through to 2004. During this time he managed an IPO for the company on the Swiss Stock Exchange, as well as a merger of IsoTis and Gensci Orthobiology.
John E. Milad is an investment manager at NBGI Ventures. He has an extensive track record in healthcare corporate finance and private equity. His recent profession experiences includes being a founder of healthcare advisory firm Insight Capital, a Special Advisor at Atlas Venture, CFO of Nitec Pharma and Associate Director of Healthcare at Nomura International. Previously, John also worked as an investment banker at Lehman Brothers and as a private equity professional at Kirkland Investors.
Philippe Pouletty, MD, is Founder and General Partner of Truffle Capital and Chairman of France Biotech, the French biotechnology association. He is a biotech industry veteran and has dual experience in Silicon Valley and France. He founded SangStat in 1988, Conjuchem in 1993 and DrugAbuse Sciences in 1995 where he served as Chief Executive Officer, President, Director and Chairman of the Board. In 1988, before SangStat, he co-founded Clonatec and served as a Director of Research from 1984 to 1988.
Erich Schlick, MD, joined Wellington Partners in October 2005. Before this, he served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head 3i Healthcare Worldwide and was responsible for numerous successful investments. Prior to venture capital, Erich spent 15 years with BASF Pharma Knoll AG, 10 years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D.
Damien Tappy is co-founder, President and Managing Partner of Endeavour Vision. Before co-founding Endeavour Vision in 2000, he was the founder and Director of the Start-up and Spin-off Program from the Swiss Federal Institute of Technology in Lausanne (EPFL). In parallel, he served as expert for new ventures creation at the Swiss Federal Commission for Technology and Innovation (CTI) in Bern.
Michael Fekete is an independent corporate advisor focused on providing strategic M&A, financing and general corporate consulting services to companies primarily in the medical products sector. He spent over 23 years as an investment banker advising medical device, pharmaceutical and biotechnology companies and was a Managing Director at various firms, including Wells Fargo, Wachovia, CIBC and Oppenheimer & Co.